These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17075977)

  • 1. Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats.
    Moal F; Veal N; Vuillemin E; Barrière E; Wang J; Fizanne L; Oberti F; Douay O; Gallois Y; Bonnefont-Rousselot D; Rousselet MC; Calès P
    World J Gastroenterol; 2006 Nov; 12(41):6639-45. PubMed ID: 17075977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.
    Croquet V; Moal F; Veal N; Wang J; Oberti F; Roux J; Vuillemin E; Gallois Y; Douay O; Chappard D; Calès P
    J Hepatol; 2002 Dec; 37(6):773-80. PubMed ID: 12445418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the nitric oxide donor molsidomine on the early stages of liver damage in rats with bile duct ligation: a biochemical and immunohistochemical approach.
    Oztürk H; Yağmur Y; Buyukbayram H; Dokucu AI; Gurel A
    Eur Surg Res; 2002; 34(4):285-90. PubMed ID: 12145554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
    Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
    United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
    Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
    Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
    Coll M; Rodriguez S; Raurell I; Ezkurdia N; Brull A; Augustin S; Guardia J; Esteban R; Martell M; Genescà J
    Hepatology; 2012 Nov; 56(5):1849-60. PubMed ID: 22610782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin response and shunting modulation in cirrhotic rats by chronic nitric oxide inhibition.
    Huang HC; Wang SS; Lee FY; Chang CC; Chang FY; Lin HC; Hou MC; Lee SD
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e265-9. PubMed ID: 17764528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
    Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
    Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation.
    Oberti F; Pilette C; Rifflet H; Maïga MY; Moreau A; Gallois Y; Girault A; le Bouil A; Le Jeune JJ; Saumet JL; Feldmann G; Calès P
    J Hepatol; 1997 Jun; 26(6):1363-71. PubMed ID: 9210625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver.
    Fiorucci S; Antonelli E; Brancaleone V; Sanpaolo L; Orlandi S; Distrutti E; Acuto G; Clerici C; Baldoni M; Del Soldato P; Morelli A
    J Hepatol; 2003 Dec; 39(6):932-9. PubMed ID: 14642608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splanchnic hyposensitivity to glypressin in a hemorrhage-transfused common bile duct-ligated rat model of portal hypertension: role of nitric oxide and bradykinin.
    Chen CT; Chu CJ; Lee FY; Chang FY; Wang SS; Lin HC; Hou MC; Wu SL; Chan CC; Huang HC; Lee SD
    Hepatogastroenterology; 2009; 56(94-95):1261-7. PubMed ID: 19950773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V-PYRRO/NO: an hepato-selective nitric oxide donor improves porcine liver hemodynamics and function after ischemia reperfusion.
    Ricciardi R; Foley DP; Quarfordt SH; Saavedra JE; Keefer LK; Wheeler SM; Donohue SE; Callery MP; Meyers WC
    Transplantation; 2001 Jan; 71(2):193-8. PubMed ID: 11213058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
    Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
    J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The liver-selective nitric oxide donor O2-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO) protects HepG2 cells against cytochrome P450 2E1-dependent toxicity.
    Gong P; Cederbaum AI; Nieto N
    Mol Pharmacol; 2004 Jan; 65(1):130-8. PubMed ID: 14722244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Rifaximin on Hepatic Fibrosis in Bile Duct-ligated Rat Model.
    Shin SK; Kwon OS; Lee JJ; Park YH; Choi CS; Jeong SH; Choi DJ; Kim YS; Kim JH
    Korean J Gastroenterol; 2017 Nov; 70(5):239-246. PubMed ID: 29161793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capsaicin treatment blocks development of hyperkinetic circulation in portal hypertensive and cirrhotic rats.
    Lee SS; Sharkey KA
    Am J Physiol; 1993 May; 264(5 Pt 1):G868-73. PubMed ID: 8498513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice.
    Liu J; Li C; Waalkes MP; Clark J; Myers P; Saavedra JE; Keefer LK
    Hepatology; 2003 Feb; 37(2):324-33. PubMed ID: 12540782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice.
    Edwards C; Feng HQ; Reynolds C; Mao L; Rockey DC
    Am J Physiol Gastrointest Liver Physiol; 2008 Jun; 294(6):G1311-7. PubMed ID: 18356534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term treatment with hepatoselective NO donor V-PYRRO/NO improves blood flow in hepatic microcirculation in liver steatosis in mice.
    Kus E; Jasiński K; Skórka T; Czyzynska-Cichon I; Chlopicki S
    Pharmacol Rep; 2018 Jun; 70(3):463-469. PubMed ID: 29631249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats.
    Huang HC; Wang SS; Hsin IF; Chang CC; Lee FY; Lin HC; Chuang CL; Lee JY; Hsieh HG; Lee SD
    Hepatology; 2012 Jul; 56(1):248-58. PubMed ID: 22290687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.